الإحصائيات الأساسية
| CIK | 1933414 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mineralys Therapeutics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 3, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-278122 and 333-289998 PROSPECTUS SUPPLEMENT (to Prospectus dated April 11, 2024) 9,803,921 Shares Common Stock We are offering 9,803,921 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “MLYS.” On September 2, 2025, the last reported sale price of our common stock on Th |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| September 3, 2025 |
Exhibit 1.1 Execution Version MINERALYS THERAPEUTICS, INC. (a Delaware corporation) 12,962,962 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 11, 2025 MINERALYS THERAPEUTICS, INC. (a Delaware corporation) 12,962,962 Shares of Common Stock UNDERWRITING AGREEMENT March 11, 2025 BofA Securities, Inc. Evercore Group L.L.C. Goldman Sachs & Co. LLC as Representatives of the several Underwrit |
|
| September 3, 2025 |
Exhibit 99.2 Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock RADNOR, PA, September 2, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and ot |
|
| September 3, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Proposed Public Offering of Common Stock RADNOR, PA, September 2, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated al |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| September 2, 2025 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 2, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-278122 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| September 2, 2025 |
As filed with the Securities and Exchange Commission on September 2, 2025 As filed with the Securities and Exchange Commission on September 2, 2025 Registration No. |
|
| September 2, 2025 |
Calculation of Filing Fee Tables S-3 Mineralys Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS T |
|
| August 12, 2025 |
Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduct |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organi |
|
| June 17, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria – Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiz |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiz |
|
| May 12, 2025 |
Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update – Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 31, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 31, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) – Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, wi |
|
| March 12, 2025 |
Exhibit 1.1 Execution Version MINERALYS THERAPEUTICS, INC. (a Delaware corporation) 12,962,962 Shares of Common Stock UNDERWRITING AGREEMENT Dated: March 11, 2025 MINERALYS THERAPEUTICS, INC. (a Delaware corporation) 12,962,962 Shares of Common Stock UNDERWRITING AGREEMENT March 11, 2025 BofA Securities, Inc. Evercore Group L.L.C. Goldman Sachs & Co. LLC as Representatives of the several Underwrit |
|
| March 12, 2025 |
Exhibit 99.2 Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock RADNOR, PA, March 11, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldoster |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 12, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Proposed Public Offering of Common Stock RADNOR, PA, March 10, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it h |
|
| March 12, 2025 |
12,962,962 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-278122 PROSPECTUS SUPPLEMENT (to Prospectus dated April 11, 2024) 12,962,962 Shares Common Stock We are offering 12,962,962 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “MLYS.” On March 11, 2025, the last reported sale price of our common stock on The Nasdaq Global S |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 10, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension – Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automa |
|
| March 10, 2025 |
SUBJECT TO COMPLETION, DATED MARCH 10, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-278122 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| February 14, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Mineralys Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value per share Rule 457(c) and Rule 457(h) |
|
| February 14, 2025 |
AGREEMENT TO MAKE A JOINT FILING EXHIBIT 1 AGREEMENT TO MAKE A JOINT FILING The undersigned hereby agree that this Schedule 13G is filed by and on behalf of each of them. |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 As filed with the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 12, 2025 |
Exhibit 10.2 MINERALYS THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract and retain Eligible Individuals who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized t |
|
| February 12, 2025 |
c. Insider Trading Compliance Policy and Procedures Exhibit 19.1 Mineralys Therapeutics, Inc. Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. |
|
| February 12, 2025 |
Exhibit 99.1 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Initiating Phase 2 trial to eval |
|
| February 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41614 MINERALYS THE |
|
| February 4, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or org |
|
| February 4, 2025 |
Exhibit 99.1 Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria – Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025 – RADNOR, PA – February 4, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused |
|
| January 8, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2025 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or orga |
|
| January 8, 2025 |
Exhibit 99.1 Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension – Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive sleep apnea represents Mineralys’ third precision, tar |
|
| November 13, 2024 |
MLYS / Mineralys Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G/A Passive Investment SC 13G/A 1 d913151dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603170101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Stateme |
|
| November 13, 2024 |
SC 13G/A 1 tm2426170d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603170101 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Stat |
|
| November 13, 2024 |
MLYS / Mineralys Therapeutics, Inc. / Catalys Pacific Fund, LP - SC 13G/A Passive Investment SC 13G/A 1 d847797dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| November 12, 2024 |
Exhibit 99.1 Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERA |
|
| November 12, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Mineralys Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value per share Rule 457(c) and Rule 457(h) |
|
| November 12, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| October 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or org |
|
| October 30, 2024 |
Exhibit 99.1 Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension – Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hyperten |
|
| September 25, 2024 |
Exhibit 99.1 Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension – On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, PA – September 2 |
|
| September 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or o |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or orga |
|
| August 13, 2024 |
Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS T |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organi |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organi |
|
| May 31, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiz |
|
| May 22, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiz |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiza |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS |
|
| May 9, 2024 |
Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update – Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD |
|
| April 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-278122 PROSPECTUS SUPPLEMENT $100,000,000 Common Stock We have entered into an ATM Equity Offering Sales Agreement (the Sales Agreement), with BofA Securities, Inc. and Evercore Group L.L.C. (each, a Sales Agent, and collectively, the Sales Agents), relating to the sale of shares of our common stock, $0.0001 par value per share, offered by this |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 9, 2024 |
Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road Suite F200 Radnor, Pennsylvania 19087 Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road Suite F200 Radnor, Pennsylvania 19087 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-3, as amended File No. 333-278122 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the Ge |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Mineralys Therapeutics, Inc. |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 21, 2024 |
Exhibit 1.2 MINERALYS THERAPEUTICS, INC. Common Stock ($0.0001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENT March 21, 2024 BofA Securities, Inc. Evercore Group L.L.C. c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Ladies and Gentlemen: Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024 As filed with the Securities and Exchange Commission on March 21, 2024 Registration No. |
|
| March 21, 2024 |
Exhibit 4.3 Mineralys Therapeutics, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions. 1 Section 1.2 Other Definitions. 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 5 Section 1.4 Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series. 5 Section 2.2 Esta |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Mineralys Therapeutics, Inc. |
|
| March 21, 2024 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 21, 2024, Mineralys Therapeutics, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. Description of Common Stock General The follo |
|
| March 21, 2024 |
Mineralys Therapeutics, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 MINERALYS THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Mineralys Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subj |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41614 MINERALYS THE |
|
| March 21, 2024 |
Exhibit 99.1 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – – Explore-CKD Phase 2 trial, a study for lorundrostat in hypertensive patients |
|
| February 15, 2024 |
EX-99.1 2 d645646dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| February 15, 2024 |
MLYS / Mineralys Therapeutics, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d645646dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 603170101 (CUSIP Number) February 12, 2024 (Date of Event Which Requires Filing of This Statement) Che |
|
| February 14, 2024 |
MLYS / Mineralys Therapeutics, Inc. / ADAMS STREET PARTNERS LLC - SC 13G Passive Investment SC 13G 1 tm245942d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 603170101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2024 |
MLYS / Mineralys Therapeutics, Inc. / Catalys Pacific Fund, LP - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 603170101 (CUSIP Number) |
|
| February 13, 2024 |
SC 13G 1 tm245871d5sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603170101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| February 13, 2024 |
EX-99.1 2 a2024021313gex991.htm EX-99.1 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy |
|
| February 12, 2024 |
MLYS / Mineralys Therapeutics, Inc. / Samsara BioCapital, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm245884d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 603170101 (CUSIP Number) Abrar Hussain Samsara BioCapital 628 Middlefield Road Palo Alto, CA 94301 650-285-4270 (Name, Addr |
|
| February 12, 2024 |
MLYS / Mineralys Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment 1)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603170101 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (N |
|
| February 8, 2024 |
Exhibit 10.1 MINERALYS THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of February 7, 2024 (the “Effective Date”), by and between Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers whose names and addresses are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Pu |
|
| February 8, 2024 |
Mineralys Therapeutics Announces $120 Million Private Placement Financing Exhibit 99.1 Mineralys Therapeutics Announces $120 Million Private Placement Financing RADNOR, Pa., February 8, 2024 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a s |
|
| February 8, 2024 |
Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or org |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or orga |
|
| January 4, 2024 |
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer Exhibit 99.1 Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer RADNOR, PA – January 4, 2024 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, |
|
| December 22, 2023 |
Exhibit 99.1 Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension – Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, PA – December 21, 2023 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage b |
|
| December 22, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| November 13, 2023 |
Exhibit 99.1 Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 – New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone i |
|
| November 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or or |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or org |
|
| November 7, 2023 |
Exhibit 99.1 Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update – On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 – – Expect to initiate planned Phase 2 Explore-CKD trial of lorundrostat alone and in combination with SGLT2 inhibitor to treat hyperten |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERA |
|
| November 2, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or org |
|
| November 2, 2023 |
Exhibit 99.1 Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting – Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension – – Endotype |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or o |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS T |
|
| August 7, 2023 |
Exhibit 99.1 Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension – – On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uncontrolled or resistant h |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| July 17, 2023 |
Exhibit 99.1 Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) – Plan to initiate a Phase 2 proof of concept trial of lorundrostat alone and in combination with an SGLT2 inhibitor for CKD in the second half of 2023 – – Profiling trial of safety in individuals with sta |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organi |
|
| May 15, 2023 |
Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update – Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023 – – Plan to initiate the second pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiz |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41614 MINERALYS |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organiza |
|
| March 22, 2023 |
8-K 1 mlys202303178k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdict |
|
| March 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdiction of incorporation or organ |
|
| March 15, 2023 |
Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-04321 MINERALYS THE |
|
| March 15, 2023 |
Description of Registered Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 1, 2023, Mineralys Therapeutics, Inc. (“we,” “us” and “our”) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. Description of Common Stock General The follow |
|
| March 15, 2023 |
Exhibit 99.1 Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 – – IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately $202.0 million, after deducting |
|
| February 24, 2023 |
MLYS / Mineralys Therapeutics Inc / Samsara BioCapital, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 603170101 (CUSIP Number) Abrar Hussain Samsara BioCapital 628 Middlefield Road Palo Alto, CA 94301 650-285-4270 (Name, Address and Telephone Number of Person Authoriz |
|
| February 24, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| February 24, 2023 |
MLYS / Mineralys Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) MINERALYS THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 603170101 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter |
|
| February 24, 2023 |
MLYS / Mineralys Therapeutics Inc / Andera Partners - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* Mineralys Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 603170101 (CUSIP Number) |
|
| February 24, 2023 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 14, 2023 |
8-K 1 mineralys-8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2023 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41614 84-1966887 (State or other jurisdi |
|
| February 14, 2023 |
Exhibit 3.2 Amended and Restated Bylaws of Mineralys Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 1 2.5 Notice of Nominations for Election t |
|
| February 14, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. Mineralys Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1.The name of the Corporation is Mineralys Therapeutics, Inc. The Corporation was incorporated under the name Cata |
|
| February 10, 2023 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Mineralys Therapeutics, Inc. |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
12,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-269282 and 333-269672 12,000,000 Shares Common Stock This is Mineralys Therapeutics, Inc.’s initial public offering. We are selling 12,000,000 shares of our common stock. The public offering price for our common stock is $16.00 per share. Currently, no public market exists for the shares of our common stock. Our common stock has been approved |
|
| February 9, 2023 |
As filed with the Securities and Exchange Commission on February 9, 2023 As filed with the Securities and Exchange Commission on February 9, 2023 Registration No. |
|
| February 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 Mineralys Therapeutics, Inc. Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share Rule 457(a) 2,300,000 $16.00 $36,800, |
|
| February 7, 2023 |
February 7, 2023 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-269282 Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, a |
|
| February 7, 2023 |
Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road, Suite F200 Radnor, PA 19087 CORRESP 1 filename1.htm Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road, Suite F200 Radnor, PA 19087 February 7, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-269282 Ladies and Gentlemen: Pursu |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1966887 (State of incorporation or organization) (I.R.S. Employer Identification No.) 150 N. Radnor C |
|
| February 2, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 Mineralys Therapeutics, Inc. Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share Rule 457(a) 11,500,000 16.00 $184,000,00 |
|
| February 2, 2023 |
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 1, 2022, as amended, by and among Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on Schedule A hereto (each, an “Investor”). WHEREAS, certain of the Investors (the “Existing Investors”) h |
|
| February 2, 2023 |
As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration No. |
|
| February 2, 2023 |
Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan Exhibit 10.3 MINERALYS THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended |
|
| February 2, 2023 |
Exhibit 10.2 MINERALYS THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in th |
|
| February 2, 2023 |
Exhibit 10.1 MINERALYS THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN (As Amended and Restated Effective June 1, 2022) 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity o |
|
| February 2, 2023 |
Exhibit 10.5 February 1, 2023 Jon Congleton Re: Amended and Restated Employment Letter Dear Jon: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated October 9, 2020, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your continued emplo |
|
| February 2, 2023 |
Exhibit 10.7 February 1, 2023 Adam Levy Re: Amended and Restated Employment Letter Dear Adam: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated March 8, 2022, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your continued employment |
|
| February 2, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.4 MINERALYS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Mineralys Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be ma |
|
| February 2, 2023 |
Exhibit 1.1 MINERALYS THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [l], 2023 MINERALYS THERAPEUTICS, INC. (a Delaware corporation) [l] Shares of Common Stock UNDERWRITING AGREEMENT [l], 2023 BofA Securities, Inc. Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated as Representatives of the several Underwriters c/o BofA Securities, |
|
| February 2, 2023 |
Exhibit 10.6 February 1, 2023 David Rodman, M.D. Re: Amended and Restated Employment Letter Dear Dr. Rodman: This amended and restated employment letter agreement (this “Agreement”) amends and restates that certain employment letter agreement (the “Prior Agreement”), dated January 8, 2021, between you and Mineralys Therapeutics, Inc. (the “Company”). This Agreement sets forth the terms of your con |
|
| February 2, 2023 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mineralys Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: |
|
| February 2, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. Mineralys Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Mineralys Therapeutics, Inc. The Corporation was incorporated under the name Cat |
|
| February 2, 2023 |
Specimen stock certificate evidencing the shares of common stock Exhibit 4.1 DELAWAR E SEAL M IN ER AL YS THERAPEUTICS, IN C. CO RPORATE May 2019 MTI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF Mineralys Therapeutics, Inc. transferable on the books of the Company in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued an |
|
| January 18, 2023 |
Form of Indemnification Agreement for Directors and Officers Exhibit 10.8 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (“Agreement”) is made as of , 20 by and between Mineralys Therapeutics, Inc. a Delaware corporation (the “Company”), and , [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements betw |
|
| January 18, 2023 |
Offer Letter Agreement, dated March 8, 2022, by and between Adam Levy and the Registrant EX-10.7 13 exhibit107-sx1a.htm EX-10.7 Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. March 8, 2022 Via Email Adam Levy [***] Re: Employment Offer Letter Dear Adam: Mineralys Therapeutics, Inc. (the “Company”) is pleased to o |
|
| January 18, 2023 |
Exhibit 3.2 BY-LAWS of CATALYS SC1, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or said meeting is |
|
| January 18, 2023 |
EX-3.4 6 exhibit34-sx1.htm EX-3.4 Exhibit 3.4 Amended and Restated Bylaws of Mineralys Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 No |
|
| January 18, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 Mineralys Therapeutics, Inc. Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(2) Equity Common Stock, par value $0.0001 per share Rule 457(o) — — $100,000,000 0.000110 |
|
| January 18, 2023 |
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 1, 2022, by and among Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on Schedule A hereto (each, an “Investor”). WHEREAS, certain of the Investors (the “Existing Investors”) hold shares o |
|
| January 18, 2023 |
Exhibit 10.2 MINERALYS THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in th |
|
| January 18, 2023 |
Offer Letter Agreement, dated October 9, 2020, by and between Jon Congleton and the Registrant Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. October 9, 2020 Via Email Jon Congleton [***] Re: Employment Offer Letter Dear Jon: Mineralys Therapeutics, Inc. (the “Company”) is pleased to offer you a position on the terms s |
|
| January 18, 2023 |
Offer Letter Agreement, dated January 8, 2021, by and between David Rodman, M.D. and the Registrant Exhibit 10.6 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. January 8th, 2021 Via Email David Rodman, MD [***] Re: Employment Offer Letter Dear Dr. Rodman: Mineralys Therapeutics, Inc. (the “Company”) is pleased to offer you a position on |
|
| January 18, 2023 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. Mineralys Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Mineralys Therapeutics, Inc. The Corporation was incorporated under the name Cat |
|
| January 18, 2023 |
As filed with the Securities and Exchange Commission on January 18, 2023 As filed with the Securities and Exchange Commission on January 18, 2023 Registration No. |
|
| January 18, 2023 |
Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan Exhibit 10.3 MINERALYS THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended |
|
| January 18, 2023 |
Exhibit 10.1 MINERALYS THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN (As Amended and Restated Effective June 1, 2022) 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity o |
|
| January 18, 2023 |
Exhibit 10.9 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT This License Agreement (the “Agreement”) made and executed as of [***], by and between Mitsubishi Tanabe Pharma Corporation, a corporation organized under the l |
|
| January 18, 2023 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mineralys Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: |
|
| December 29, 2022 |
DRS/A 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on December 29, 2022 as Amendment No. 2 to the draft Registration Statement Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in it |
|
| December 29, 2022 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid Washington, |
|
| December 7, 2022 |
DRS/A 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on December 7, 2022 as Amendment No. 1 to the draft Registration Statement Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its |
|
| December 6, 2022 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid Washington, |
|
| November 4, 2022 |
EX-10.1 5 filename5.htm Exhibit 10.1 MINERALYS THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN (As Amended and Restated Effective June 1, 2022) 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing su |
|
| November 4, 2022 |
Exhibit 10.9 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT This License Agreement (the “Agreement”) made and executed as of [***], by and between Mitsubishi Tanabe Pharma Corporation, a corporation organized under the l |
|
| November 4, 2022 |
EX-10.6 7 filename7.htm Exhibit 10.6 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. January 8th, 2021 Via Email David Rodman, MD [***] Re: Employment Offer Letter Dear Dr. Rodman: Mineralys Therapeutics, Inc. (the “Company”) is pleased to |
|
| November 4, 2022 |
EX-10.5 6 filename6.htm Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. October 9, 2020 Via Email Jon Congleton [***] Re: Employment Offer Letter Dear Jon: Mineralys Therapeutics, Inc. (the “Company”) is pleased to offer you a |
|
| November 4, 2022 |
As confidentially submitted to the Securities and Exchange Commission on November 4, 2022 DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on November 4, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 84-1966887 (State or other jurisd |
|
| November 4, 2022 |
Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. March 8, 2022 Via Email Adam Levy [***] Re: Employment Offer Letter Dear Adam: Mineralys Therapeutics, Inc. (the “Company”) is pleased to offer you a position on the terms set fo |
|
| November 4, 2022 |
BY-LAWS CATALYS SC1, INC. (the “Corporation”) EX-3.2 3 filename3.htm Exhibit 3.2 BY-LAWS of CATALYS SC1, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is establis |
|
| November 4, 2022 |
EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MINERALYS THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mineralys Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”) |
|
| November 4, 2022 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of June 1, 2022, by and among Mineralys Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on Schedule A hereto (each, an “Investor”). WHEREAS, certain of the Investors (the “Existing Investors”) hold shares o |
